Abstract:

Anti-IgE monoclonal antibodies have been approved for the treatment of asthma and chronic urticaria, and anti-IgE monoclonal antibodies combined with allergen immunotherapy (AIT) have attracted widespread attention as an adjunctive therapy for allergic diseases. Studies have shown that the addition of anti-IgE monoclonal antibodies during or before AIT treatment significantly reduces the frequency and severity of AIT adverse reactions, significantly improves the symptom scores, and shortens the time required to achieve maintenance doses. Larger, high-quality, placebo-controlled trials are still needed to better identify the beneficiaries of anti-IgE monoclonal antibodies in conjunction with AIT, as well as the optimal dose and duration of treatment, and to assess long-term benefits and conduct cost-benefit analysis. This article reviews the application of anti-IgE monoclonal antibodies as adjunctive therapy in AIT.

Key words: anti-IgE monoclonal antibody, allergen immunotherapy, adjunctive therapy